Therefore, we can support that immunohistochemical homogeneous PTEN loss is predominantly linked to ERG fusions (ERG-positive immunostaining), a mechanism mostly seen in prostate adenocarcinomas of low grade. This evidence concerns the gene PTEN and prostate adenocarcinoma.